



# MELD-ATG

A CLINICAL TRIAL BY **INNODIA**

Building on the strong basis of INNODIA, with its unique European clinical and fundamental research network for the study of type 1 diabetes (T1D), we propose an ambitious programme that aims at the prevention and cure of T1D through objectives that focus on innovation.

## Objective of the study

This clinical study with anti-thymocyte globulin (ATG), supplied by Sanofi, aims to examine the activity and dose schedule of ATG in children and young adults who have recently been diagnosed with T1D in order to reduce disease progression at the earliest possible time.

## Conditions for participation

- ◇ Are you aged between 5 and 25?
- ◇ Has type 1 diabetes been diagnosed in you in the past 6 weeks?

## Course of the study

### Visits during follow-up

